GleamWall
中文EN

IMMP IMMUTEP Ltd IFRS Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1506184 · Reporting currency AUD · Fiscal year ends 06/30

Financial factors as of 2025-06-30 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY31.8%
TTM net income YoY-43.8%
TTM EPS YoY-18.5%
Revenue 3-yr CAGR15.2%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin-594.6%
FCF margin-601.0%
EBITDA margin—

Returns

ROE-36.9%
ROA-34.3%
ROIC (approx.)—
Asset turnover0.06x

Leverage & solvency

Liabilities / assets8.5%
Debt / equity0.00x
Current ratio11.69x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.01x
Accruals ratio0.3%
Payout ratio—
Capex / revenue0.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Unit: AUD FY20252025-06-30FY20242024-06-30
Income statement
Revenue10.33M7.84M
R&D expense49.78M31.47M
SG&A expense8.64M8.85M
Interest expense37,07830,594
Pretax income-61.43M-42.72M
Income tax00
Net income-61.43M-42.72M
EPS (basic)-0.04-0.04
EPS (diluted)-0.04-0.04
Weighted avg. shares (diluted)1.46B1.20B
Balance sheet
Cash & equivalents67.41M161.79M
Short-term investments62.28M20.09M
Receivables9.87M7.35M
Current assets149.10M191.35M
PP&E, netmay include right-of-use assets (IFRS)63,45863,145
Total assets156.98M201.58M
Current liabilities12.76M10.49M
Total liabilities13.35M12.06M
Shareholders' equity143.64M189.52M
Cash flow statement
Operating cash flow-62.05M-34.82M
Capital expenditure45,76929,215
Free cash flow-62.10M-34.85M
Investing cash flow-38.53M-21.02M
Financing cash flow-525,12195.18M
Depreciation & amortization2.39M2.26M
Stock-based compensation1.16M1.80M

Free plan shows the latest 2 periods; Pro shows all 10 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company does not report gross profit in XBRL.

· Amounts are in the company's reporting currency, AUD, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.